CL2013001877A1 - Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus. - Google Patents

Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.

Info

Publication number: CL2013001877A1
Authority: CL; Chile
Prior art keywords: pestivirus; vaccine; relieve; symptoms; virus
Prior art date: 2010-12-27

Application number

CL2013001877A

Other languages

English (en)

Inventor

Dale Wade Weise

James Robert Harris

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-27

Filing date

2013-06-25

Publication date

2014-03-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45531546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001877(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-03-07 Publication of CL2013001877A1 publication Critical patent/CL2013001877A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CL2013001877A 2010-12-27 2013-06-25 Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus. CL2013001877A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201061427361P	2010-12-27	2010-12-27

Publications (1)

Publication Number	Publication Date
CL2013001877A1 true CL2013001877A1 (es)	2014-03-07

Family

ID=45531546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001877A CL2013001877A1 (es)	2010-12-27	2013-06-25	Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.

Country Status (20)

Country	Link
US (1)	US20130280294A1 (es)
EP (1)	EP2658570B1 (es)
JP (1)	JP6053036B2 (es)
KR (1)	KR101554080B1 (es)
CN (1)	CN103347534B (es)
AU (1)	AU2011352800B2 (es)
BR (1)	BR112013016503A2 (es)
CA (1)	CA2822825C (es)
CL (1)	CL2013001877A1 (es)
CO (1)	CO6761399A2 (es)
ES (1)	ES2709190T3 (es)
MX (1)	MX351380B (es)
NZ (1)	NZ611531A (es)
PE (1)	PE20140871A1 (es)
PH (1)	PH12013501373B1 (es)
PL (1)	PL2658570T3 (es)
PT (1)	PT2658570T (es)
RU (1)	RU2595873C2 (es)
SG (1)	SG191396A1 (es)
WO (1)	WO2012092053A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR084358A1 (es) *	2010-12-27	2013-05-08	Lilly Co Eli	Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
US9480739B2 (en) *	2013-03-15	2016-11-01	Intervet Inc.	Bovine virus vaccines that are liquid stable
CN107970443A (zh) *	2016-12-28	2018-05-01	浙江海隆生物科技有限公司	牛病毒性腹泻病毒e2蛋白亚单位疫苗组合物及其制备方法和应用
CN107823639B (zh) *	2017-11-10	2020-10-02	齐鲁动物保健品有限公司	牛病毒性腹泻病毒灭活疫苗及其制备方法
KR101960017B1 (ko) *	2018-04-09	2019-07-15	전북대학교 산학협력단	호흡기 질병의 원인체를 검출하기 위한 조성물 및 이를 이용한 방법
KR101960016B1 (ko) *	2018-04-09	2019-07-15	전북대학교 산학협력단	호흡기 질병의 원인체를 검출하기 위한 조성물 및 이를 이용한 방법
KR102101208B1 (ko)	2019-10-16	2020-04-17	주식회사 모투스	비산먼지 제거 기능이 있는 런닝머신
CN112034169A (zh) *	2020-08-27	2020-12-04	华威特（江苏）生物制药有限公司	用于检测牛病毒性腹泻病毒1型的直接免疫荧光试剂及其试剂盒
CN113207733B (zh) *	2021-05-28	2022-09-09	杨国胜	一种具有麻醉作用的畜牧用耳标
CN114634996B (zh) *	2022-02-28	2024-05-07	广东海大畜牧兽医研究院有限公司	用于检测牛呼吸道疾病的引物探针组合、试剂盒及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
DE3329892A1 (de)	1983-08-18	1985-03-07	Köster, Hubert, Prof. Dr., 2000 Hamburg	Verfahren zur herstellung von oligonucleotiden
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FR2596761B1 (fr)	1986-04-08	1988-05-20	Commissariat Energie Atomique	Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
US5491225A (en)	1991-12-19	1996-02-13	Hoffmann-La Roche Inc.	PCR primers for detection of legionella species and methods for controlling visual intensity in hybridization assays
NZ285324A (en) *	1994-05-10	1998-08-26	American Home Prod	Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
US7563449B2 (en) *	2003-04-21	2009-07-21	Pfizer Inc,	Methods for reducing cattle reproductive diseases
US7361357B2 (en) *	2003-07-29	2008-04-22	Pfizer Inc.	Safe mutant viral vaccines
EP1727562B1 (en) *	2004-03-17	2008-06-18	Pharmacia & Upjohn Company LLC	Method of vaccination against testicular bvdv infection
US20070031450A1 (en) *	2005-08-04	2007-02-08	Wyeth	Stabilizers for veterinary vaccines
US20090068223A1 (en) *	2005-11-15	2009-03-12	Boehringer Ingelheim Vetmedica, Inc.	Combination vaccine comprising an attenuated bovine viral diarrhea virus
AU2006338210A1 (en) *	2005-12-14	2007-08-23	The Board Of Regents Of The University Of Oklahoma	RNA virus vaccines and methods

2011
- 2011-12-21 CA CA2822825A patent/CA2822825C/en not_active Expired - Fee Related
- 2011-12-21 PL PL11813490T patent/PL2658570T3/pl unknown
- 2011-12-21 US US13/995,688 patent/US20130280294A1/en not_active Abandoned
- 2011-12-21 MX MX2013007584A patent/MX351380B/es active IP Right Grant
- 2011-12-21 BR BR112013016503A patent/BR112013016503A2/pt not_active Application Discontinuation
- 2011-12-21 PE PE2013001482A patent/PE20140871A1/es active IP Right Grant
- 2011-12-21 EP EP11813490.7A patent/EP2658570B1/en active Active
- 2011-12-21 RU RU2013128921/15A patent/RU2595873C2/ru not_active IP Right Cessation
- 2011-12-21 ES ES11813490T patent/ES2709190T3/es active Active
- 2011-12-21 AU AU2011352800A patent/AU2011352800B2/en not_active Ceased
- 2011-12-21 CN CN201180067439.0A patent/CN103347534B/zh not_active Expired - Fee Related
- 2011-12-21 NZ NZ61153111A patent/NZ611531A/en not_active IP Right Cessation
- 2011-12-21 JP JP2013547556A patent/JP6053036B2/ja not_active Expired - Fee Related
- 2011-12-21 SG SG2013050117A patent/SG191396A1/en unknown
- 2011-12-21 WO PCT/US2011/066384 patent/WO2012092053A1/en not_active Ceased
- 2011-12-21 PH PH1/2013/501373A patent/PH12013501373B1/en unknown
- 2011-12-21 KR KR1020137019872A patent/KR101554080B1/ko not_active Expired - Fee Related
- 2011-12-21 PT PT11813490T patent/PT2658570T/pt unknown
2013
- 2013-06-25 CL CL2013001877A patent/CL2013001877A1/es unknown
- 2013-07-10 CO CO13164014A patent/CO6761399A2/es unknown

Also Published As

Publication number	Publication date
EP2658570A1 (en)	2013-11-06
NZ611531A (en)	2015-04-24
PE20140871A1 (es)	2014-07-19
MX351380B (es)	2017-10-12
JP6053036B2 (ja)	2016-12-27
ES2709190T3 (es)	2019-04-15
BR112013016503A2 (pt)	2018-05-22
CN103347534B (zh)	2018-09-11
PH12013501373A1 (es)	2013-08-28
RU2013128921A (ru)	2015-02-10
SG191396A1 (en)	2013-08-30
KR20130109220A (ko)	2013-10-07
JP2014502619A (ja)	2014-02-03
CA2822825C (en)	2016-02-09
CA2822825A1 (en)	2012-07-05
MX2013007584A (es)	2013-10-17
AU2011352800B2 (en)	2015-09-03
EP2658570B1 (en)	2018-11-28
RU2595873C2 (ru)	2016-08-27
US20130280294A1 (en)	2013-10-24
PL2658570T3 (pl)	2019-05-31
CO6761399A2 (es)	2013-09-30
KR101554080B1 (ko)	2015-09-17
CN103347534A (zh)	2013-10-09
PT2658570T (pt)	2019-02-08
WO2012092053A1 (en)	2012-07-05
AU2011352800A1 (en)	2013-06-20
PH12013501373B1 (en)	2019-05-10

Similar Documents

Publication	Publication Date	Title
CL2013001877A1 (es)	2014-03-07	Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
CL2016001580A1 (es)	2017-01-13	Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
CL2012001959A1 (es)	2012-12-07	Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
BR112012020839A2 (pt)	2017-11-21	vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
ECSP099685A (es)	2009-11-30	Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
CL2013000755A1 (es)	2013-10-04	Compuestos derivados de analogos nucleosidicos; composicion farmaceutica; y su uso para tratar una infeccion viral, tal como adenovirus, coronavirus, flavivirus, hcv, entre otros.
ECSP15011603A (es)	2015-12-31	Subunidades de vacunas de inmersión para peces
CL2018001159A1 (es)	2018-06-22	Vacuna para adenovirus aviar (divisional de solicitud n° 358-2016)
CL2012001176A1 (es)	2012-08-31	Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
CO6761348A2 (es)	2013-09-30	Compuestos antivirales
BRPI1013394A2 (pt)	2016-06-21	"composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
CL2012000620A1 (es)	2013-09-06	Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
EA201591888A1 (ru)	2016-05-31	Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CL2012003643A1 (es)	2013-08-02	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CL2013001428A1 (es)	2014-06-27	Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
CL2013001141A1 (es)	2013-10-04	Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CO6440541A2 (es)	2012-05-15	Virus de diarrea viral bovina con una proteina erns modificada
CL2013001940A1 (es)	2014-02-14	Composicion que comprende al menos una fibra soluble y al menos uno seleccionado entre un probiotico vivo, un probiotico inactivo, un medio de cultivo de un probiotico y una combinacion de dos o mas de las tres opciones anteriores; y su uso para aliviar, tratar y/o prevenir sintomas y/o condiciones relacionadas con estres cronico.
UY32457A (es)	2011-01-31	Vacuna del virus del dengue inactivado
AR080313A1 (es)	2012-03-28	Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
CL2009001298A1 (es)	2009-12-28	Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
CL2014000393A1 (es)	2014-08-01	Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CL2011000262A1 (es)	2011-05-06	Virus de bronquitis infecciosa (bi) derivado de un virus similar a qx-bi; composicion de vacuna que comprende dicho virus; procedimiento para preparar dicho virus.
UY32721A (es)	2011-01-31	Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
CL2011003043A1 (es)	2012-07-20	Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue.